bioMérieux – First-Half 2016 Results

31 August, 2016

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the six months ended June 30, 2016. The statements had been reviewed by the Statutory Auditors.

  • Strong growth in sales, up 10.9% at constant exchange rates and scope of consolidation:
    • €1,001 million in sales
    • Up 7.2% as reported
  • Sharp 22% improvement in contributive operating income before non-recurring items, as robust sales momentum offset the negative currency effect
  • 2016 financial targets revised:
    • Organic sales growth could end the year at or above the higher end of the previously targeted 6.0% to 8.0% range.
    • Full-year contributive operating income before non-recurring items is now expected

Alexandre Mérieux, Chief Executive Officer, said: "Backed by its expanded business portfolio and broad global market footprint, bioMérieux has accelerated its organic sales growth and improved its operating margins. Based on these good results, management now believes that the Group will meet the upper range of the targets set for the year, while continuing to effectively invest to support its long-term strategy."

2016 Objectives

Based on the first-half performance and currently available data, management now believes that organic sales growth, at constant exchange rates and scope of consolidation, could end the year at or above the higher end of the previously targeted 6.0% to 8.0% range.

Second-half growth is expected to come in slightly below the first-half performance, with a greater proportion of instrument sales. In addition, full-year performance will be influenced by the timing and intensity of the seasonal flu epidemic in the United States. Lastly, bioMérieux will continue to invest as required to lead its long-term strategy of innovation and geographic expansion, its two major sustainable growth drivers for the years ahead.

In this environment, and given the persistent volatility in the currency markets, bioMérieux could deliver full-year contributive operating income before non-recurring items at around the top of the initially targeted €265 million to €290 million range.

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2015, revenues reached €1,965 million with 90% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market
(Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN: FR0010096479).
Corporate website: www.biomerieux.com. Investor website: www.biomerieux-finance.com.

Contacts

Investor Relations

bioMérieux
Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux
Aurore Sergeant
Tel.: +33 (0)4 78 87 54 75
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64
lheilbronn@image7.fr

Download the Full Press Release:

Download
Pioneering Diagnostics